MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Erasca Inc

Gesloten

2.43 -2.8

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.4

Max

2.74

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.9M

-34M

Winstmarge

-768.16

Werknemers

103

EBITDA

-2.5M

-38M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+39.48% upside

Dividenden

By Dow Jones

Volgende Winsten

10 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

242M

661M

Vorige openingsprijs

5.23

Vorige sluitingsprijs

2.43

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Erasca Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 okt 2025, 16:58 UTC

Winsten

BMW Trims 2025 View, Citing Weaker Performance in China

7 okt 2025, 23:43 UTC

Marktinformatie

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 okt 2025, 23:36 UTC

Marktinformatie

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 okt 2025, 23:19 UTC

Marktinformatie

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 okt 2025, 22:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 22:50 UTC

Marktinformatie

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 okt 2025, 22:40 UTC

Marktinformatie

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 okt 2025, 21:56 UTC

Marktinformatie

Global Equities Roundup: Market Talk

7 okt 2025, 21:56 UTC

Marktinformatie

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 okt 2025, 20:44 UTC

Populaire aandelen

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 okt 2025, 19:42 UTC

Marktinformatie

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 okt 2025, 19:23 UTC

Acquisities, Fusies, Overnames

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 okt 2025, 19:07 UTC

Marktinformatie

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 okt 2025, 19:02 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 okt 2025, 16:15 UTC

Marktinformatie

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 okt 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

7 okt 2025, 15:37 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 15:37 UTC

Marktinformatie

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 okt 2025, 15:33 UTC

Marktinformatie

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 okt 2025, 15:25 UTC

Marktinformatie

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 okt 2025, 15:15 UTC

Marktinformatie

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 okt 2025, 15:04 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

7 okt 2025, 15:04 UTC

Marktinformatie

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 okt 2025, 14:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 14:56 UTC

Marktinformatie

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 okt 2025, 14:52 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Erasca Inc Prognose

Koersdoel

By TipRanks

39.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.25 USD  39.48%

Hoogste 6 USD

Laagste 1 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Erasca Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

2

Buy

1

Hold

1

Sell

Technische score

By Trading Central

1.39 / 1.44Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Very Strong Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
help-icon Live chat